Lonza has announced plans to establish a new laboratory in Cambridge, Massachusetts (US), in an effort to broaden the scope of its Early Development Services (EDS) in North America.
The nearby Boston biotech community's 17,000 square foot centre broadens Lonza's current EDS product range.
Due to its existing EDS facility, customers already benefit from improved bio therapeutic candidate safety and manufacturability.
Customers will also be able to assess, reduce risk, and improve potential biotherapeutic drug candidates at the new facility to increase their chances of success.
Moreover, they will also benefit from the early detection and mitigation of potential issues prior to clinical trials, which lowers the risk of drug candidate failure and could shorten the time to clinic.
Services include a range of in silico, early non-GMP protein translation, and in vitro immunity procedures.
The new centre will offer the same services, including early non-GMP expression and in vitro immuno-safety assessment.
It will broaden Lonza's Early Development Services into the US, primarily benefiting small- to mid-sized biotech companies who are developing biologic drug candidates in the preclinical stage.
With the opening of this facility, Lonza will be able to help customers throughout the full product life cycle within its US site network—from early development through commercialization.
In May 2023, the facility is anticipated to start operations.